Pfizer Inc.(PFE)Company Profile & BusinessNYSE
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands.
In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Pfizer Inc. (PFE) between Aug 13, 2024 and Aug 12, 2026 consists of 39 total transactions. Among these, company executives and board members conducted 37 buys (totaling 2,531,283 shares) and 2 sells (totaling 5,278 shares). This activity resulted in a net change of 2,526,005 shares, reflecting net buying interest with an estimated net acquisitions value of $54.12M.
39 insider transactions found. Showing 10 of 39 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| BOURLA ALBERT | Chief Executive Officer | 38,000 | $1.00 | Aug 12, 2026 |
| Unknown Insider | Chairman & CEO | 38,000 | $26.34 | Aug 12, 2026 |
| BUCKLEY MORTIMER J. | Director | 37,632 | $0.96 | Aug 5, 2026 |
| BLAYLOCK RONALD E | Director | 39,231 | $1.00 | Aug 5, 2026 |
| DAMICO JENNIFER B. | Officer | 3,278 | $0.08 | Aug 5, 2026 |
| Unknown Insider | Director | 39,231 | $25.46 | Aug 5, 2026 |
| Buckley Mortimer J | Director | 37,632 | $25.52 | Aug 5, 2026 |
| DAMICO JENNIFER B. | SVP & Controller | -3,278 | $25.40 | Aug 5, 2026 |
| DAMICO JENNIFER B. | Officer | 2,000 | $0.05 | Jun 9, 2026 |
| DAMICO JENNIFER B. | SVP & Controller | -2,000 | $25.70 | Jun 9, 2026 |
Explore More Analysis for PFE
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.